applepharmaceutical@gmail.com
drugs

PRODUCT DETAILS

Brand Name : Lynparza
Composition : Olaparib
Strength availability : 50mg
Manufactured by : Myriad genetic Laboratories
Pack : 112 capsules
for MORE INFORMATION !!!

Lynparza 50mg is a type of targeted therapy called a PARP (oral poly (adenosine diphosphate–ribose) polymerase inhibitor)which has promising anti neoplasticaction in patients with metastatic breast cancer and a germline BRCA mutation.
Lynparza 50mg is an enzyme included in DNA repair and will act against cancers in people with hereditary BRCA1 or BRCA2 mutations, which involve some ovarian, breast and prostate cancer
Lynparza 50mg is a prescription drug which used under the supervision of medical practioners

INDICATION

Lynparza 50mg is used for the treatment in patients with first line maintenance BRCAm advanced ovarian cancer
Lynparza 50mg is used for the treatment in patients with maintenance recurrent ovarian cancer.
Lynparza 50mg is used for the treatment in patients withadvanced gBRCAm ovarian cancer
Lynparza is indicated for the treatment in patients with HER2 – negative metastatic breast cancer.

DOSAGE

Ovarian cancer :
Maintenance treatment of recurrent ovarian cancer
The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID
Continue treatment until disease progression or unacceptable toxicity
Monotherapy for advanced BRCA – mutated ovarian cancer
The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID
The capsules usual dose is 400mg (eight 50mg- mg capsules) PO BID
Continue treatment until disease progression or unacceptable toxicity.
Maintenancetreatment for advanced BRCA-mutated ovarian cancer
The tablet usual dose is 300mg (two 150mg – mg tablets) PO BID
Follow the treatment until disease progression, undesirable toxicity or completion of 2 years of treatment
Finishing of 2 years of treatment
• Patients with full response (no radiologic evidence): discontinue treatment
• Patients with indication of disease and may asset from continuous treatment: cure beyond 2 years.

MECHANISM

Olaparib belongs to targeted therapy. Olaparib is also called as poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, involving PARP1, PARP2, and PARP3. PARP enzymes are containing in DNA transcription, cell cycle regulation, and DNA repair.
Olaparib belongs to potent oral PARP inhibitor which induces synthetic fatality in BRCA 1/2 deficient tumor cells via the formation of double-stranded DNA cutsthat cannot be accurately repaired, which causesdivision of cellular homeostasis and cell death

ADME

Absorption: Maximum plasma concentration 1 to 3 hours
Distribution: volume of distribution 167 +/-196 L, plasma protein binding is 82%
Metabolism: Primarily metabolised by CYP3A4
Elimination: Excreted through the urine 44% and 42% through the feces.
Half – life of Lynparza 11.9 hours

PRECAUTION

• Haematological toxicity will cause in patients treated with Lynparza contain diagnoses or findings of generally mild or moderate anaemia, neutropenia, thrombocytopenia and lymphopenia.
• When Lynparza monotherapy administrated to patient the incidence of myelodysplastic syndrome will occur. • On basis of mechanism of action (PARP inhibition), Lynparza could cause risk to fetal when administered to a pregnant woman.
• Lynparza combination with strong or moderate CYP3A inhibitors is not recommended.

DRUG INTERACTION

Concomitant use with myelosuppressive anticancer agents contains DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.
Combination of strong CYP3A inhibitors (itraconazole, telithromycin, clarithromycin,) will increase Olaparib plasma concentration.
Lynparza combination with strong CYP3A inducers (itraconazole, telithromycin, clarithromycin,) will decrease Olaparib plasma concentration.

CONTRAINDICATION

None.

MISSED DOSE

If dose is missed the have the dose immediately before next dose timing reaches or skip the missed dose and continue the regular schedule.
Consult doctors regarding missed dose.

STORAGE

Store at 20℃ to 25℃

SIDE EFFECTS

Common side effects for patients taking Olaparib :
• Decreased white blood cell count
• Abdominal pain
• Vomiting
• Upper respiratory tract infection
• Anemia
• Decreased neutrophils
• Musculoskeletal pain
• Diarrhea
• Decreased platelet count
• Decreased Haemoglobin
• Nausea
• Fatigue (including weakness)
• Increased serum creatinine
• Myalgia
• Headache
• Skin rash
• Back pain
• Taste changes
• Cough
• Swelling
• Dizziness
• Constipation
• Urinary tract infection
• Heartburn
• loss of appetite
• Shortness of breath

We'd Like to Hear From You!

PRESCRIPTION POLICY

1. myapplepharma.com, a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.
2. myapplepharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.
3. If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.
4. The drug information provided in the myapplepharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.
5. myapplepharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from myapplepharma.com.
6. At myapplepharma.com, a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether to accept this product or any other medicine. Only a health care provider is knowledge and training to decide that a medicine suitable for a specific patient. This information does not support any drug as safe, are effective or approved for the treatment of any patient or health condition. It's simple a brief overview of general information about this product. It does not include all information on possible applications, indications, warnings, precautions, interactions, adverse effects or risks that may be relevant to this product. This information is not specific medical advice and does not replace information obtained from your health care provider. You should check with your health care provider for complete information about the risks and benefits of using this product.